First-line | Hospitalization policy | |
---|---|---|
treatment | Recommendations (R) or standard practice (SP) | |
Belgium | Atovaquone-proguanilArtemether-lumefantrine | SP : hospitalization (ambulatory treatment possible under certain conditions) |
Quinine + cycline | ||
France | Atovaquone-proguanil Artemether-lumefantrine | R : Ambulatory treatment possible on the basis of specific clinical and biological parameters |
Germany | Atovaquone-proguanil Artemether-lumefantrine | R : hospitalization recommended until treatment completed and patient parasite-free |
Mefloquine | ||
Italy | Atovaquone-proguanil | SP : hospitalization (ambulatory treatment possible under certain conditions) |
Mefloquine | ||
Spain | Quinine + cycline or clindamycin Atovaquone-proguanil | SP: hospitalization (ambulatory treatment possible under certain conditions) |
Switzerland | Artemether-lumefantrine Atovaquone-proguanil | SP: hospitalization (ambulatory treatment possible under certain conditions) |
United Kingdom | Atovaquone-proguanil | R : Systematically, at least 24 h |
Artemether-lumefantrine | ||
Quinine + cyclines | ||
The Netherlands | Atovaquone-proguanil Artemether-lumefantrine | SP: hospitalization (ambulatory treatment possible under certain conditions) |
Quinine + cyclines | ||
Chloroquine* |